Articles producció científica> Medicina i Cirurgia

Hypercholesterolemia and cardiovascular disease: Focus on high cardiovascular risk patients

  • Dades identificatives

    Identificador: imarina:9162447
    Autors:
    Watts, Gerald F.Catapano, Alberico L.Masana, LuisZambon, AlbertoPirillo, AngelaTokgozoglu, Lale
    Resum:
    The widespread use of statins has largely improved the treatment of hypercholesterolemia, but many patients still fail to achieve the LDL-C targets recommended by guidelines. Furthermore, some patients continue to present a very high cardiovascular (CV) risk or even an extreme risk despite being well treated, mainly due to the presence of co-morbidities such as diabetes or peripheral artery disease, which significantly increase their global CV risk. For these very high CV risk patients, the most recent European guidelines have reviewed the LDL-C goals and recommend an LDL-C reduction of at least 50% and a goal of <55 mg/dL or even <40 mg/dL. Recent clinical trials have shown that patient stratification based on the presence or absence of atherothrombotic risk factors may represent a valuable tool to identify patients at extremely high CV risk who may benefit more from an aggressive LDL-C-lowering approach. In these patients it may be appropriate to aim for the lowest LDL-C level, independently of recommended goals, with all the available pharmacological approaches. (c) 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
  • Altres:

    Autor segons l'article: Watts, Gerald F.; Catapano, Alberico L.; Masana, Luis; Zambon, Alberto; Pirillo, Angela; Tokgozoglu, Lale;
    Departament: Medicina i Cirurgia
    Autor/s de la URV: Masana Marín, Luis
    Paraules clau: Hypercholesterolemia High risk patients Cardiovascular disease
    Resum: The widespread use of statins has largely improved the treatment of hypercholesterolemia, but many patients still fail to achieve the LDL-C targets recommended by guidelines. Furthermore, some patients continue to present a very high cardiovascular (CV) risk or even an extreme risk despite being well treated, mainly due to the presence of co-morbidities such as diabetes or peripheral artery disease, which significantly increase their global CV risk. For these very high CV risk patients, the most recent European guidelines have reviewed the LDL-C goals and recommend an LDL-C reduction of at least 50% and a goal of <55 mg/dL or even <40 mg/dL. Recent clinical trials have shown that patient stratification based on the presence or absence of atherothrombotic risk factors may represent a valuable tool to identify patients at extremely high CV risk who may benefit more from an aggressive LDL-C-lowering approach. In these patients it may be appropriate to aim for the lowest LDL-C level, independently of recommended goals, with all the available pharmacological approaches. (c) 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
    Àrees temàtiques: Peripheral vascular disease Medicine (miscellaneous) Medicina iii Medicina i Internal medicine Farmacia Ciências biológicas iii Cardiology and cardiovascular medicine Biotecnología
    Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
    Adreça de correu electrònic de l'autor: luis.masana@urv.cat
    Identificador de l'autor: 0000-0002-0789-4954
    Data d'alta del registre: 2023-02-19
    Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
    Enllaç font original: https://www.sciencedirect.com/science/article/pii/S1567568821000088?via%3Dihub
    Referència a l'article segons font original: Atherosclerosis Supplements. 42 E30-E34
    Referència de l'ítem segons les normes APA: Watts, Gerald F.; Catapano, Alberico L.; Masana, Luis; Zambon, Alberto; Pirillo, Angela; Tokgozoglu, Lale; (2020). Hypercholesterolemia and cardiovascular disease: Focus on high cardiovascular risk patients. Atherosclerosis Supplements, 42(), E30-E34. DOI: 10.1016/j.atherosclerosissup.2021.01.006
    URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
    DOI de l'article: 10.1016/j.atherosclerosissup.2021.01.006
    Entitat: Universitat Rovira i Virgili
    Any de publicació de la revista: 2020
    Tipus de publicació: Journal Publications
  • Paraules clau:

    Cardiology and Cardiovascular Medicine,Internal Medicine,Medicine (Miscellaneous),Peripheral Vascular Disease
    Hypercholesterolemia
    High risk patients
    Cardiovascular disease
    Peripheral vascular disease
    Medicine (miscellaneous)
    Medicina iii
    Medicina i
    Internal medicine
    Farmacia
    Ciências biológicas iii
    Cardiology and cardiovascular medicine
    Biotecnología
  • Documents:

  • Cerca a google

    Search to google scholar